New Medtronic Neurovascular Co-Lab™
Platform drives collaboration and connections among start-ups,
physicians, and institutions; aims to improve stroke treatment and
access for patients worldwide
DUBLIN, Oct. 26, 2022 /PRNewswire/ -- Medtronic plc
(NYSE: MDT), a global leader in healthcare technology, today
announced the launch of Medtronic Neurovascular Co-Lab™
Platform designed to accelerate urgently needed innovation in
stroke care and treatment.
The company is harnessing its market-leading position and
trusted partner reputation to create a platform that will
ultimately advance technology concepts that have the highest
potential to positively impact millions of stroke patients.
Innovators, entrepreneurs, and physicians will be able to
collaborate, enhance, and share their breakthrough concepts and
products. With the launch of Medtronic Neurovascular
Co-Lab™ Platform, Medtronic is deepening its commitment
to advance stroke innovation as the world prepares to recognize
World Stroke Day on October 29,
2022.
"We need to act now to prioritize the best concepts and
strongest products to ensure they reach more patients sooner," said
Dan Volz, president of the Medtronic
Neurovascular business, which is part of the Neuroscience
Portfolio. "Clinicians and innovators are passionate about
improving stroke care, and the neurovascular technology market is
brimming with ideas, improvements, and would-be therapies in need
of development. Our platform will provide both an infrastructure
and a process to realize viable opportunities on a previously
unmatched scale."
Medtronic Neurovascular Co-Lab™ Platform will
help bring neurovascular innovations to life. The process will be
both transparent and collaborative, ensuring opportunities advance
effectively and responsibly. The platform will be launched on
October 29, World Stroke Day.
"What's fascinating about the neurovascular field is that we
still have so much to discover about the brain. Medtronic has
always invested in innovative stroke treatment technologies leading
the standard of care and advancing the practice of neurosurgery,"
said Brett Wall, executive vice
president and president of the Medtronic Neuroscience Portfolio.
"The neurovascular market has enormous growth potential, and we
invite innovative start-ups, physicians, venture-capital firms and
inventors to collaborate with us as we set out to change stroke
care as we know it today. With more than 90,000 employees across
150 countries – combined with our proven record in stroke
innovation – Medtronic is positioned well to help address this
urgent challenge."
Medtronic Neurovascular Co-Lab™ Platform is an
always-on virtual portal for innovator submissions, which are then
assessed and prioritized to determine a potential path forward.
Chosen opportunities will be advanced based on their individual
needs, including exposing innovators to Medtronic's network of
experts, thought leaders and partners for collaboration, clinical
study funding, and strategic and directional guidance.
Medtronic welcomes innovations at every stage of development to
move them to the next level; however,
high-priority opportunities are high-potential, late-stage
clinical and commercial-stage products and technology, followed by
physician-led improvements to existing products. To learn more, or
input a submission, please visit Medtronic Neurovascular
Co-Lab™ Platform at
www.medtronic.com/neurovascular-co-lab.
About the stroke challenge
Advancing stroke care is
critical and urgent. Globally, 15 million people suffer from stroke
annually. Of those, 5 million people die and another 5 million are
left permanently disabled.1 Yet, the second leading
cause of death and the third leading cause of disability globally
often goes untreated. 2 Most people experience ischemic
strokes in which blood flow to the brain is blocked by a clot.
Studies indicate that only about 10 to 14 percent receive
clot-dissolving treatment that can stop the onset of stroke
symptoms.3
Furthermore, the use of mechanical thrombectomy, a surgical
treatment for stroke and the standard of care for large vessel
occlusion strokes remains extremely low. In the U.S., the 2019
estimate of thrombectomies was below 40,000, while the number of
patients who could benefit from thrombectomy was between 200,000
and 350,000.4
About the Neurovascular business at Medtronic
With the
largest neurovascular technology business in the world, Medtronic
Neurovascular led evidence-based medicine in neurointervention with
five landmark studies published in The New England Journal of
Medicine in 2015. Its clinical and regulatory leadership and
bold approach shaped the current guidelines for treating
strokes.5
About Medtronic
Bold thinking. Bolder actions. We are
Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global
healthcare technology company that boldly attacks the most
challenging health problems facing humanity by searching out and
finding solutions. Our Mission — to alleviate pain, restore health,
and extend life — unites a global team of 90,000+ passionate people
across 150 countries. Our technologies and therapies treat 70
health conditions and include cardiac devices, surgical robotics,
insulin pumps, surgical tools, patient monitoring systems, and
more. Powered by our diverse knowledge, insatiable curiosity, and
desire to help all those who need it, we deliver innovative
technologies that transform the lives of two people every second,
every hour, every day. Expect more from us as we empower
insight-driven care, experiences that put people first, and better
outcomes for all. In everything we do, we are engineering the
extraordinary. For more information on Medtronic (NYSE:MDT), visit
www.Medtronic.com and follow @Medtronic on Twitter and
LinkedIn.
Any forward-looking statements are subject to risks and
uncertainties such as those described in Medtronic's periodic
reports on file with the Securities and Exchange Commission. Actual
results may differ materially from anticipated results.
References:
- Stroke, Cerebrovascular accident. World Health Organization,
http://www.emro.who.int/health-topics/stroke-cerebrovascular-accident/index.html.
Accessed September 6, 2022.
- What we do. World Stroke Organization.
https://www.world-stroke.org/what-we-do. Accessed October 6, 2022.
- Skolarus, et al. Marked Regional Variation in Acute Stroke
Treatment Among Medicare Beneficiaries. Stroke. (2015) 46:
1890-1896.
- The Global Push for Mechanical Thrombectomy in Stroke Care.
NeurologyLive, December 2020, Volume
3, Issue 7.
https://www.neurologylive.com/view/the-global-push-for-mechanical-thrombectomy-in-stroke-care
- The 2015 AHA/ASA Focused Update of the 2013 Guidelines for the
Early Management of Patients with Acute Ischemic Stroke Regarding
Endovascular Treatment.
Contacts:
|
|
|
|
Kelli Lynch
|
Ryan
Weispfenning
|
Public Relations
|
Investor
Relations
|
+1-203-500-3328
|
+1-763-505-4626
|
Photo -
https://mma.prnewswire.com/media/1925040/NV_colab_image_Medtronic.jpg
Logo -
https://mma.prnewswire.com/media/1657690/Medtronic_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/announcing-the-launch-of-medtronic-neurovascular-co-lab-platform-to-accelerate-innovation-in-stroke-treatment-301653909.html